Solid Biosciences (SLDB) Change in Receivables (2021 - 2022)
Quarterly results put Change in Receivables at -$14000.0 for Q2 2022, down 333.33% from a year ago — trailing twelve months through Dec 2022 was -$110000.0 (down 200.0% YoY), and the annual figure for FY2022 was -$110000.0, down 200.0%.
Solid Biosciences has reported Change in Receivables over the past 2 years, most recently at -$14000.0 for Q2 2022.
- Change in Receivables reached -$14000.0 in Q2 2022 per SLDB's latest filing, up from -$96000.0 in the prior quarter.
- Across five years, Change in Receivables topped out at $308000.0 in Q3 2021 and bottomed at -$484000.0 in Q4 2021.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | 208,524.00 |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | -39.80 Mn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | -1.20 Mn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 110.42 Mn |
| 10 | Solid Biosciences | 713.77 Mn | 333.09 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | -14,000.00 |
| Jun 30, 2022 | -14,000.00 |
| Mar 31, 2022 | -96,000.00 |
| Mar 31, 2022 | -96,000.00 |
| Dec 31, 2021 | -484,000.00 |
| Dec 31, 2021 | -484,000.00 |
| Sep 30, 2021 | 308,000.00 |
| Sep 30, 2021 | 308,000.00 |
| Jun 30, 2021 | 6,000.00 |
| Jun 30, 2021 | 6,000.00 |
| Mar 31, 2021 | 280,000.00 |
| Mar 31, 2021 | 280,000.00 |